Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2022 | Story Rulanzen Martin | Photo Rulanzen Martin
Renata van Reenen
Renata van Reenen has been a South African Sign Language (SASL) champion since primary school, and she is using her postgraduate degree to further SASL in higher education.

Renata van Reenen, a master’s student at the University of the Free State (UFS), recalls how a school talk in 1998 by Deaf activist Johan Gouws instilled in her a kind of ‘duty’ to become a champion for Deaf people. Van Reenen, who in 1987 became the first Deaf child in South Africa to receive a cochlear implant, says it was at this talk that she realised that, as a Deaf person, she has her own language, identity, and culture – and that she is not “a person with a disability”. 

Van Reenen is currently a language facilitator in the UFS Department of South African Sign Language (SASL) and Deaf Studies, and she believes that Deaf students should be empowered to embrace their attributes. Her interests include exploring different sign languages around the world, Deaf issues, and how Deaf children are supported in schools for the Deaf. “One of my hobbies is to put my creative ideas on paper, and I would like to develop and record these stories in SASL so they can be accessible to Deaf schools as resource materials,” she says. “These materials would then also be accessible when teaching the subject South African Sign Language as a Home Language.”

Van Reenen, who worked as an assistant teacher at a school for the Deaf for seven years, is passionate about SASL and the lived experiences of the Deaf. We asked her to share some views on empowering the Deaf and SASL: 

Why is it important to empower Deaf students?

When I was 17, I had no Deaf identity. I did not understand sign language and how it was used – when the Deaf person gave a speech at the school, it changed my life. I realised that I am a Deaf person with my own language, identity, and culture, and that I am not a person with a disability. I strongly believe that Deaf students need to be empowered to fully embrace their identity, language, and culture, and through this expectance show the world who we are. My favourite motto I always share with my Deaf learners is: “Believe in yourself, show them what you can do.” I also encourage them to continuously teach Hearing students the beautiful language, as the famous Deaf quote states: “Sign language is the noblest gift God has given to Deaf people.” George Veditz, the former president of the National Association of the Deaf of the United States, said, “As long as we have Deaf people on Earth, we will have signs.” He protected our language at a time (the early 20th century) when the world strongly believed that Deaf people had to learn through oralism and had to learn spoken language in order to function as a “normal person” alongside hearing people.

As a Deaf person, do you believe the UFS community is doing enough to accommodate you, and how do you feel about being part of the Department of SASL and Deaf Studies? 

When I received a link for a workshop I had to attend, I was so overwhelmed when I saw the interpreter on the video link, and knew that it would be extremely helpful for me during my research. The UFS Centre for Universal Access and Disability Support made sure I have full access to any workshops the university provides. It is amazing that my supervisor can also sign. That made me feel at home, being in a Deaf world without communication barriers. The department is an amazing team that supports and encourages me during my studies.

What will you be doing in honour of Deaf Awareness Month?

The SASL Department and I, along with Deaf Studies, have organised a “Signing Space” event in September to bring Deaf and Hearing students together to socialise with each other. This event will give Hearing students the opportunity to learn about the Deaf world. During this event I will give a small presentation such as “Poetry in SASL” that will show that Deaf people have their own literature, and that it forms part of their language, SASL. We will not only focus on presentations but also on fun activities, such as games that are prominent within the Deaf community. 

Why did you decide to pursue your MA at the UFS? 

During the coronavirus pandemic I applied to the University of Gallaudet in Washington, DC to study for a Master of Education in Sign Language degree. Gallaudet is the world's only university in which all programmes and services are specifically designed to accommodate deaf and hard of hearing students. I was accepted to study further and to ultimately become a teacher or lecturer. My aim was to train Deaf adults to qualify in different areas of SASL, ranging from SASL Linguistics, SASL Pedagogy, SASL Media Production, and so forth. In an ideal world these could be offered as short courses through some tertiary institutions which already offer SASL on undergraduate and postgraduate levels. Unfortunately, I did not have enough support, but I did not let it stop my dream. I decided to change my university of choice and applied at the University of the Free State. I am pursuing my MA degree and continuing my studies as a Deaf person. The University of the Free State is providing and recognising SASL. This is a positive step, as South African Sign Language will soon be the twelfth official language of South Africa.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept